Tenax Therapeutics Inc (TENX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $73.77M
Last updated: Nov 17, 2026 at 4:25 PM ET
Tenax Therapeutics Inc (TENX) Stock Chart
Tenax Therapeutics (TENX) has a latest price of $1.42 on Nov 17, 2026, 92.7% below its 52-week high of $19.40. Its price fell 80.0% over the past 12 months. The month-end price fell 100.0% over the 10 years through Oct 2026, a compound annual decline of 64.1%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $62,400.00 in Dec 2016 and its lowest $1.79 in Oct 2026, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart TENX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for TENX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 25.3%, and over 6 months it fell 87.6%. The month-end price fell 87.9% over the 3 years through Oct 2026, a compound annual decline of 50.6%.
| Period | Change |
|---|---|
| 1 month | -6.6% |
| 3 months | -25.3% |
| 6 months | -87.6% |
| 12 months | -80.0% |
| 12 months, with dividends | -80.0% |
| Period | Change | Per year |
|---|---|---|
| 3 years | -87.9% | -50.6% |
| 5 years | -99.9% | -76.4% |
| 10 years | -100.0% | -64.1% |
Price by Year
Its best calendar year was 2025, when the price rose 96.9%, and its weakest was 2022, when it fell 89.3%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $1.79 | -85.3% |
| 2025 | $12.19 | +96.9% |
| 2024 | $6.19 | -71.8% |
| 2023 | $21.97 | -87.7% |
| 2022 | $178.24 | -89.3% |
| 2021 | $1,664.00 | -44.1% |
| 2020 | $2,976.00 | +31.9% |
| 2019 | $2,256.00 | +16.5% |
| 2018 | $1,936.00 | -87.7% |
| 2017 | $15,680.00 | -74.9% |
Trading Range
The price is 20.0% below its 50-day average of $1.77 and 84.7% below its 200-day average of $9.29.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $1.42 | |
| 52-week high | $19.40 | -92.7% |
| 52-week low | $1.31 | +8.4% |
| 50-day average | $1.77 | -20.0% |
| 200-day average | $9.29 | -84.7% |
Price Risk
Over 3 years, its largest fall from a peak was 95.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.32 |
| Largest fall, 1 year | -92.6% |
| Largest fall, 3 years | -95.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About TENX
What is TENX's 1-year price change?
Tenax Therapeutics's price fell 80.0% over the past 12 months. With dividends included, the 12-month total return was -80.0%.
What is TENX's 5-year price change?
Tenax Therapeutics's month-end price fell 99.9% over the 5 years through Oct 2026, a compound annual decline of 76.4%. These figures leave out dividends.
What is TENX's 52-week high and low?
Tenax Therapeutics's 52-week high is $19.40 and its 52-week low is $1.31. Its latest price of $1.42 on Nov 17, 2026 is 92.7% below the high.
What is TENX's beta?
Tenax Therapeutics's 1-year beta against the S&P 500 is 1.32, so its price has moved more than the market over the past year. Its largest fall from a peak over the past year was 92.6%.
Is the TENX chart free?
Yes. Advanced Charting for TENX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
TENX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors